0000899243-15-003061.txt : 20150813 0000899243-15-003061.hdr.sgml : 20150813 20150813163059 ACCESSION NUMBER: 0000899243-15-003061 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150803 FILED AS OF DATE: 20150813 DATE AS OF CHANGE: 20150813 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rolfe Lindsey CENTRAL INDEX KEY: 0001650504 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 151051068 MAIL ADDRESS: STREET 1: C/O CLOVIS ONCOLOGY, INC. STREET 2: 499 ILLINOIS STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2015-08-03 0 0001466301 Clovis Oncology, Inc. CLVS 0001650504 Rolfe Lindsey C/O CLOVIS ONCOLOGY, INC., 2525 28TH STREET, SUITE 100 BOULDER CO 80301 0 1 0 0 See remarks Employee stock option (right to buy) 3.08 2020-04-07 Common Stock 31034 D Employee stock option (right to buy) 3.28 2021-03-01 Common Stock 17241 D Employee stock option (right to buy) 24.74 2022-03-01 Common Stock 30000 D Employee stock option (right to buy) 21.81 2023-03-01 Common Stock 40000 D Employee stock option (right to buy) 73.98 2024-01-10 Common Stock 17500 D Employee stock option (right to buy) 78.38 2024-02-27 Common Stock 35000 D Employee stock option (right to buy) 79.05 2025-03-02 Common Stock 12500 D Employee stock option (right to buy) 85.65 2025-08-03 Common Stock 35000 D The option vested as to 25% of the shares on April 1, 2011 and the remainder vested in substantially equal installments over the 36 months immediately following such date. The option vested as to 25% of the shares on March 1, 2012 and the remainder vested in substantially equal installments over the 36 months immediately following such date. The option is immediately exercisable as to both vested and unvested shares. The option vested as to 25% of the shares on March 1, 2013 and the remainder vest in substantially equal installments over the 36 months immediately following such date. To the extent the reporting person exercises the option as to unvested shares, the reporting person will receive restricted shares that will vest in accordance with the vesting schedule for the option. The option vested as to 25% of the shares on March 1, 2014 and the remainder vest in substantially equal installments over the 36 months immediately following such date. The option vested as to 25% of the shares on January 10, 2015 and the remainder vest in substantially equal installments over the 36 months immediately following such date. The option vested as to 25% of the shares on February 27, 2015 and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The option shall vest as to 25% of the shares on March 2, 2016, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. The option shall vest as to 25% of the shares on August 3, 2016, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance /s/ Lindsey Rolfe 2015-08-13